Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
June 2025
The global progressive pulmonary fibrosis (PPF) treatment market size is calculated at US$ 0.6 in 2024, grew to US$ 0.69 billion in 2025, and is projected to reach around US$ 2.45 billion by 2034. The market is projected to expand at a CAGR of 15.21% between 2025 and 2034.
The progressive pulmonary fibrosis (PPF) treatment market is expanding due to the growing awareness of fibrotic interstitial lung diseases and the rising aging population. Recent advancements in diagnostic devices, such as biomarker testing and CT scans, have allowed early and precise diagnostics. North America is dominated in the market due to growing healthcare innovation and increasing investment in new therapies, while Asia Pacific is the fastest growing due to strong healthcare infrastructure and growing R&D activity.
| Metric | Details |
| Market Size in 2025 | USD 0.69 Billion |
| Projected Market Size in 2034 | USD 2.45 Billion |
| CAGR (2025 - 2034) | 15.21% |
| Leading Region | North America share by 44% |
| Market Segmentation | By Drug Class, By Disease Subtype, By Route of Administration, By End User, By Region |
| Top Key Players | Boehringer Ingelheim, Roche Holding AG, Galapagos NV, FibroGen Inc., Bristol Myers Squibb, Bellerophon Therapeutics, United Therapeutics Corporation, Vicore Pharma, Pliant Therapeutics, Liminal BioSciences, Galecto Inc., Verona Pharma, Gilead Sciences, Kadmon (Sanofi), Algernon Pharmaceuticals, Zydus Lifesciences, Sun Pharmaceutical Industries, Cipla Ltd., Kissei Pharmaceutical n, MediciNova Inc. |
The Progressive Pulmonary Fibrosis (PPF) Treatment Market includes pharmaceuticals, biologics, and supportive therapies aimed at managing non-idiopathic forms of pulmonary fibrosis that exhibit progressive behavior (i.e., worsening respiratory symptoms, decline in lung function, and increased fibrosis despite treatment).
PPF may stem from various interstitial lung diseases (ILDs) such as connective tissue disease-associated ILD (CTD-ILD), chronic hypersensitivity pneumonitis, and unclassifiable ILDs. The market is gaining traction with the expansion of antifibrotic therapies beyond idiopathic pulmonary fibrosis (IPF), supported by updated clinical guidelines and regulatory approvals.
Integration of AI in progressive pulmonary fibrosis (PPF) treatment drives the growth of the market as AI-based technology has huge potential to enhance early diagnosis, modified treatment, and predictive accuracy, eventually attractive the quality of life for PPF patients. AI analyzes huge amounts of data rapidly, helps physicians identify diseases earlier, plan treatments more precisely, and manage patient records efficiently.
AI-driven algorithms are being broadly applied in the prognosis of PPF and other diseases, along with fully utilizing CT scans data, achieving objective quantification, enhancing assessment efficiency, and obtaining novel landscapes from large-scale data. AI helps overcome long-term challenges through automating tasks like patient identification, trial design, data management, and compliance, which drives the growth of the market.
Increasing Prevalence of PPF
The higher occurrence of progressive pulmonary fibrosis is linked to specific genetic factors and cigarette smoking. Consequently, physiotherapists can recommend that patients avoid or quit smoking to reduce the risk of idiopathic pulmonary fibrosis. The estimated prevalence of progressive fibrosing ILDs is up to 28 cases per 100,000 people, derived from data on fibrosing ILDs and survey estimates of how many patients develop a progressive form. This prevalence contributes to the expanding market for treatments targeting progressive pulmonary fibrosis (PPF).
Challenges in Treating PPF
Recent challenges in treating progressive pulmonary fibrosis (PPF) include difficulties in predicting disease progression, limited effectiveness of current therapies, and the necessity for more personalized and effective treatment strategies. These issues hinder the growth of the PPF treatment market.
Emerging Treatment Option for the PPF
Emerging treatment options include stem cell therapy, immunomodulatory agents, and new pharmacological targets like PDE4B inhibitors. Stem cell therapy has the potential to repair damaged lung tissue and regulate immune responses, while immunomodulatory agents focus on reducing lung inflammation and fibrosis. Ongoing research and clinical trials provide hope for innovative treatments that could revolutionize IPF management and improve patient outcomes, creating opportunities in the progressive pulmonary fibrosis (PPF) treatment market.
By drug class, the antifibrotic agents segment led the progressive pulmonary fibrosis (PPF) treatment market, due to these includes nintedanib (Ofev) and pirfenidone (Esbriet®). These medications are known as anti-fibrotic agents, which means that they have been shown in clinical trials to slow down the rate of fibrosis or damage in the lungs.
Antifibrotic therapy helps the respiratory functions of the lungs. There remains a scientific dilemma regarding whether to strengthen or discontinue the immunomodulatory therapy, present an antifibrotic agent, or use a combination of these two strategies in patients representing progression.
On the other hand, the pipeline biologics & anti-inflammatory agents’ segment is projected to experience the fastest CAGR from 2025 to 2035, as it is active in slowing IPF progression and lowering the rate of decline in FVC in patients with PPF compared to placebos. Different groups of medications prescribed to lower inflammation include azathioprine, cyclophosphamide, and mycophenolate mofetil, which function by suppressing the immune system.
By Disease Subtype, connective tissue disease-associated ILD (CTD-ILD) dominated the progressive pulmonary fibrosis (PPF) treatment market in 2024, as connective tissue diseases (CTDs) are often associated with interstitial lung disease (ILD), expressively impacting their morbidity and mortality. Active management is crucial for enhancing survival.
The unclassifiable interstitial lung disease (uILD) segment is projected to grow at the highest CAGR from 2025 to 2035, as unclassifiable interstitial lung disease (ILD) includes a subset of ILDs that cannot be classified according to the current diagnostic framework. Unclassifiable ILD shows the final common pathway of fibrotic diseases of the lung, and regardless of the early insult or cause.
By route of administration, the oral segment led the market in 2024, due to this type of medication administration is a convenient, affordable, and most commonly used medication administration route. The primary site of drug absorption is generally the small intestine, and the bioavailability of the medication is influenced by the amount of drug absorbed in the intestinal epithelium.
The injectable biologics segment is projected to experience the fastest CAGR from 2025 to 2035, as biologics subcutaneous delivery gained prominence due to its patient-friendly method. Simultaneously, progressive drug delivery systems such as autoinjectors, infusion pumps, and wearable infusers have also been developed to simplify patient access to injectable therapies. The number of new small-molecule and biologic drug products approved for parenteral administration has increased in recent years, containing drug products for subcutaneous administration.
By end user, the hospitals & specialty pulmonary clinics segment dominated in the progressive pulmonary fibrosis (PPF) treatment market in 2024, as hospitals and specialty pulmonary clinics play a significant role in managing and treating progressive pulmonary fibrosis (PPF), which provides nintedanib and pirfenidone in the treatment of PPF. Lung transplantation is a suitable treatment for some patients who have advanced PPF. Targeted treatments supplemented with oxygen therapy and pulmonary rehabilitation support enhance breathing and slow the progress of the disease, which helps in managing progressive pulmonary fibrosis symptoms.
On the other hand, the continuous flow systems segment is expected to grow at the fastest CAGR over the forecast period, 2025 to 2035, as it offers inclusive care, caters to specific patient requirements, and is more valued for patients with pulmonary fibrosis (PF). The importance of a patient-centered care strategy is rooted in the random progression of the disease in PPF. Home healthcare providers support to management of common PF symptoms such as breathlessness, anxiety, fatigue, and cough. This also involves processes like pursed-lip breathing, energy conservation strategies, and administration of medication.
North America dominated the progressive pulmonary fibrosis (PPF) treatment market share by 44% in 2024, as the increasing prevalence of lung diseases due to high smoking rates, occupations or industries with increased risk for PPF, and increasing access to health care for screening and detection of PPF. The presence of advanced healthcare infrastructure and high healthcare expenditure drives the growth of the market.
For Instance,
In the United States, based to the National Institutes of Health (NIH), about 100,000 people in the United States have IPF. Approximately 30,000 to 40,000 new cases are diagnosed each year. Worldwide, IPF affects 13 to 20 out of every 100,000 people.
Increasing early adoption of advanced technology to treat progressive pulmonary fibrosis, such as high-throughput genomics, proteomics, high-resolution computed tomography (HRCT), precision medicine, and antifibrotic therapies, contributes to the growth of the market.
For Instance,
Canada is well-positioned to be a main player in the advanced manufacturing of nanomedicine. According to the Canadian NanoBusiness Alliance, over 130 organizations are presently involved in nanotechnology in Canada. Virtually all actions are conducted in the vicinity of five nanotechnology hubs such as Edmonton, Ottawa, Montreal, Toronto, and Vancouver, which drives the growth of the market.
Asia Pacific is estimated to be the fastest-growing progressive pulmonary fibrosis (PPF) treatment market during the forecast period, as the adoption of advanced diagnostic tools, increasing targeted therapies, and the adoption of early detection technology are involved in the management of progressive pulmonary fibrosis treatment. Growing government support for healthcare facilities and increasing investment in medical care services drive the growth of the market.
China has initiated a number of policies to enhance lung health, such as the Healthy China Initiative (2020-2023), the 'Happy Breathing' programme. The Chinese government has shown a consistent commitment toward the prevention and management of PPF, which drives the market growth. Respiratory physicians are involved in the diagnosis as well as treatment of lung diseases, including the administration of chemotherapy in China, which contributes to the growth of the market.
India's chronic respiratory disease burden is alarming, with high PPF and asthma-related deaths. Major contributing factors are factors are air pollution, smoking, indoor air pollution, and occupational hazards, this increasing the demand for advanced progressive pulmonary treatment. Growing awareness related to lung health is also contributing to the growth of the market.
Europe is expected to grow significantly in the progressive pulmonary fibrosis (PPF) treatment market during the forecast period, as increasing clinical trials, the presence of huge research centres, and collaboration between healthcare organizations and institutions drive the growth of the market.
In Germany, increasing prevalence of interstitial lung diseases, particularly in the aging population, which is increasing the demand for modern therapies. Increasing awareness among respiratory practitioners is leading to early detection and treatment. High presence of biotech and pharmaceutical companies drives the growth of the market.
In the UK, the presence of a strong healthcare infrastructure with access to specialized pulmonary centers and early diagnosis devices, such as high-resolution CT scans, drives the growth of the market.
In February 2025, Dr. Shashank Deshpande, Head of Human Pharma and Member of the Board of Managing Directors at Boehringer Ingelheim, Stated, “The positive FIBRONEER™-ILD topline result shows the potential of nerandomilast in progressive pulmonary fibrosis. The hope is that the safety and tolerability profile we are initially seeing could potentially help to reduce treatment challenges.” (Source - Boehringer Ingelheim)
By Drug Class
By Disease Subtype
By Route of Administration
By End User
By Region
June 2025
June 2025
February 2025
April 2025